The McQuade Center for Strategic Research and Development (MSRD) and Eikonizo Therapeutics have entered a collaboration to advance potential therapies for rare diseases, including amyotrophic lateral sclerosis (ALS). “We are dedicated to seeking out and supporting novel treatments for complex and rare diseases,” Robert McQuade, PhD, president of MSRD and chief strategic officer at Otsuka Pharmaceutical, said in a press release. MSRD, established in 2019 by the Otsuka Pharmaceutical business in the U.S., seeks to identify early-stage…

You must be logged in to read/download the full post.